Comstock Mining (LODE) – Solid Execution

Wednesday, November 18, 2020

Comstock Mining (LODE)

Solid Execution

Comstock Mining Inc is a mining company with a focus on gold and silver deposits in the Comstock and Silver City mining districts in Nevada. Its operations are divided into two segments, namely mining and real estate. Its mining projects include The Lucerne Resource area, the Dayton Resource area, the Spring Valley exploration target, the Northern Extension, Northern Targets and Occidental areas. The Real Estate segment involves land, real estate rental properties and a hotel, restaurant & bar provided by the Gold Hill Hotel located in Gold Hill, Nevada just south of Virginia City and the Daney Ranch, located just south of Silver City. The majority revenues are generated from the real estate segment.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Third quarter financial results. Comstock Mining generated third quarter net income of $17.3 million, or $0.54 per share, compared with net income of $386.9 thousand, or $0.02 per share during the prior year period and our estimate of $0.51. The increase relative to last year was largely attributed to transaction and investment gains. While revenue was in line with our estimate, gain on the sale of membership interests in Comstock Mining LLC was modestly higher and so was other income. While our 2021 estimate is unchanged, we updated our 2020 EPS estimates to $0.55 from $0.54.

    Advancing Dayton and Spring Valley.  Comstock recently received the results of an airborne geophysical survey of the Dayton resource area and Spring Valley exploration targets that commenced in September and was completed in October. Comstock will compile a structural interpretation of the Dayton resource area which will provide the framework for a new resource model and identify a list of drill …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Seanergy Maritime (SHIP) – Upcoming 3Q2020 Call Will Focus on Dry Bulk Market and Debt Refinancing

Wednesday, November 18, 2020

Seanergy Maritime (SHIP)

Upcoming 3Q2020 Call Will Focus on Dry Bulk Market and Debt Refinancing

Seanergy Maritime Holdings Corp., an international shipping company, provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. Seanergy Maritime Holdings Corp. is the only pure-play Capesize shipping company listed in the US capital markets. Seanergy provides marine dry bulk transportation services through a modern fleet of 10 Capesize vessels, with total capacity of approximately 1,748,581 dwt and an average fleet age of about 9.8 years. The Company is incorporated in the Marshall Islands with executive offices in Athens, Greece and an office in Hong Kong. The Company’s common shares trade on the Nasdaq Capital Market under the symbol “SHIP” and class A warrants under “SHIPW”.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    3Q2020 operating results out this morning before market opens. Call today at 10:30am EST. Call number is 877-553-9962 and code is Seanergy. We are looking for TCE revenue of $15.3 million and TCE rates of $16.0k. We forecast EBITDA of $7.5 million and net income of $3.2 million, or $0.07/share. Please note that reported 3Q2020 net income will include a gain of ~$5.0 million ($0.11/share) from the debt refinancing in July.

    Fine-tuning 2020 EBITDA estimate ahead of earnings call to reflect recent dry bulk market softness.  3Q2020 Cape TCE rates ranged from mid-teens to mid-$30k/day range. 4Q2020 is off to a softer start and current average is now in the $15k-$20k/day range. We are moving our 2020 EBITDA estimate to $17.5 million from $19.8 million to reflect updated TCE rate data and the expected timing voyage charters …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Cocrystal Pharma Inc. (COCP) – Q3 EPS Pipeline Remains on Track

Tuesday, November 17, 2020

Cocrystal Pharma Inc. (COCP)

Q3 EPS: Pipeline Remains on Track

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Q3 2020 financial results. In 3Q, Cocrystal’s net loss was $2.7 million. In the 9-months of 2020, net loss was $8.1 million. The company ended the quarter with $31.8 million in cash and cash equivalents. Earnings per share (EPS) loss was ($0.05) in the quarter.

    Model update.  We updated our estimates, according to the reported numbers and reflecting the increase in operating expenses attributed to the additional clinical trial commencement. We now forecast $2.0 million, $2.1 million, and $2.4 million in revenues, $12.8 million, $14.5 million, and $15.8 million operating expenses, and ($0.20), ($0.18), and ($0.11) in EPS for F2020, F2021 and F2021 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Comstock (LODE) – Announces Positive Nine-months Earnings

 

Comstock Mining Announces Positive Nine-months Earnings of $0.63 Per Share: Recognizes $18.3 Million Gain on Lucerne Sale

 

Virginia City, NV (November 17, 2020) Comstock Mining Inc. (the “Company”) (NYSE American: LODE) announced financial updates (unaudited) and strategic highlights for the third quarter and year to date:

Selected Strategic Highlights

  • Completed the sale of the Lucerne mine to Tonogold Resources Inc. (“Tonogold”) for total cash, stock and debt consideration of approximately $18.8 million, plus Tonogold’s assumption of certain current and future obligations, and recognized a gain on the sale of approximately $18.3 million;
  • Retained Investment in Tonogold share securities valued at $9.7 million at September 30, 2020;
  • Retained Receivable in Tonogold secured note valued at $6.4 million at September 30, 2020;
  • Extinguished its $4.8 million Senior Secured Debenture that was due later this year via a combination of cash proceeds from the Lucerne mine sale and unsecured promissory notes with favorable, extended terms;
  • Installed and commenced the Mercury Clean Up LLC (“MCU”) Comstock mercury remediation pilot;
  • Shipped and landed through MCU Philippines Inc. (“MCU-P”), the first landmark Philippines mercury remediation system, working together with our joint venture partner Clean Ore Solutions OPC;
  • Completed an airborne geophysical survey of the Dayton-Spring Valley exploration complex;
  • Expanded the airborne geophysical survey over all of the Company’s Comstock District properties;
  • Contracted to lease, with an option to sell, the Daney Ranch for $2.7 million to a drilling company; and
  • Extended the $10.1 million sale of Comstock’s two Silver Springs, NV properties until December 31, 2020.

Unaudited Third Quarter and Year To Date 2020 Selected Financial Highlights

  • Costs applicable to mining decreased $296,023 during the three months ended September 30, 2020, as compared to the same period in 2019, as a result of certain assets becoming fully depreciated. These costs consist solely of depreciation expense on temporarily idled processing equipment;
  • Real estate operating costs increased $690,306 during the three months ended September 30, 2020, as compared to the same period in 2019, almost solely due to depreciation recorded during the third quarter that would have been charged for previous periods, on the Gold Hill Hotel and Daney Ranch properties;
  • Exploration and pre-development costs increased $152,978 during the three months ended September 30, 2020, as compared to the same period in 2019, primarily due to the costs of conducting an airborne geophysical survey of the Company’s resource areas and exploration targets;
  • Interest expense decreased $15,140 during the three months ended September 30, 2020, as compared to the same period in 2019, as a result of lower average debt outstanding, including the retirement of the remaining Senior Secured Debenture in August 2020;
  • Net income was $17.3 million, or $0.54 per share for the three months ended September 30, 2020, as compared to $0.4 million, or $0.02 per share in the prior comparable period, driven by transaction gains;
  • Net income was $18.3 million, or $0.63 per share for the nine months ended September 30, 2020, as compared to a net loss of $3.5 million, or ($0.20) per share in the prior comparable period, driven by transaction and investment gains;
  • Invested $1.9 million (in cash and stock) to date in MCU, as of September 30, 2020;
  • Invested $1.0 million (in cash) to date in MCU-P, as of September 30, 2020;
  • Total assets were $48.2 million, including current assets of $26.0 million, at September 30, 2020;
  • Debt obligations totaled $4.8 million at September 30, 2020; reduced to $2.5 million by October 10; and
  • Cash and cash equivalents at September 30, 2020, were $1.7 million.

Mr. Corrado De Gasperis, Executive Chairman and CEO stated, “Our successful sale of Lucerne has eliminated substantially all of our debt and recorded an $18 plus million gain and expectations of full-year profit for 2020, all while reducing our operating expenses and positioning our balance sheet for growth. We believe that our resource-based technology, properties, plant and equipment, and existing gold and silver mineral properties are undervalued. Our strategic plan includes establishing and growing the value of our existing mineral and royalty properties, commercializing and growing a global, ESG-compliant, profitable mercury remediation business, while still monetizing over $25 million in assets over the next fifteen months, for funding that growth.”

Comstock Mining’s Corporate Growth

The Company’s goal is to grow per-share value by commercializing environment-enhancing, precious and strategic-metal-based products and processes that generate a rate of predictable cash flow (throughput) and increase the long-term enterprise value of our northern Nevada based platform. The next three years are dedicated to delivering that value by achieving the performance objectives listed below:

Establish and grow the value of our mineral properties:

  • Establish the Dayton Resource area’s maiden, stand-alone mineral resource estimate;
  • Expand the Dayton-Spring Valley Complex through exploration drilling and geophysical modelling;
  • Develop the expanded Dayton-SV Complex toward full economic feasibility, supporting a decision to mine;
  • Entitle the Dayton-SV Complex with geotechnical, metallurgical, environmental studies and permitting; and
  • Validate the Comstock NSR Royalty portfolio (Lucerne Mine, Occidental Lode, Comstock Lode, etc.).

Commercialize a global, ESG-compliant, profitable, mercury remediation system:

  • Establish the technical efficacy of MCU’s Comstock Mercury System, and protect the intellectual property;
  • Initiate and operate the first international mercury remediation project by deploying MCU’s second and third mercury remediation systems into the Philippines; and
  • Identify, evaluate and prioritize a pipeline of potential mercury remediation projects; then deploy the third and fourth mercury remediation projects, producing extended, superior cash flow returns.

Monetize non-strategic assets and build a quality organization:

  • Monetize our third-party, junior mining securities responsibly, for $12.5 million or more;
  • Monetize our non-mining assets for $12.5 million, excluding the Gold Hill Hotel;
  • Grow the value of our Opportunity Zone investments to over $30 million; and
  • Deploy a systemic organization, capable of accelerating growth and handling complexity.

The strategic plan is designed to deliver per-share value over the next three years, while positioning the Company for continued growth beyond 2023.

Comstock Mining’s Corporate Realignment

Comstock Mining Inc. is the parent company that wholly owns the realigned subsidiaries and is expanding its mineral resources, mercury remediation operations and royalty portfolios.

Mr. De Gasperis continued, “The realignment enables partnerships and transactions that increase value-creating opportunities and accelerate our precious and strategic-metal-based products and process growth. Our goal is to deliver over $500 million of value, or at least $12 per share, from our existing assets and the commercialization of these environmentally friendly metal processing and mining technologies, partnerships and ventures.”

Comstock Exploration and Development

Our district-wide exploration and development plans contemplate three specific, geological areas that the Company has organized into wholly-owned subsidiaries called Comstock Exploration and Development LLC, Comstock Northern Exploration LLC, and Comstock Mining LLC. Comstock Exploration and Development LLC includes the Dayton and Spring Valley areas. Comstock Northern Exploration LLC includes the Occidental and Gold Hill exploration targets now leased to Tonogold, and Comstock Mining LLC, recently acquired by Tonogold, includes the Lucerne properties. These exploration targets represent over 7 miles of mineralized strike length, with current and historical grades of gold and silver, and significant historical mine production.

Comstock Processing LLC

Comstock Processing LLC (“CPL”), owns all of the property, plant, equipment, and permits for the crushing, agglomerating, leaching, Merrill Crowe processing, mercury retort, refining, and metallurgical operations located at 1200 American Flat Road, Virginia City, Nevada. The facilities represent a fully permitted platform, best positioned for implementing our Strategic Focus on high-value, cash-generating, precious and strategic metal-based activities.

To date, Comstock Processing has entered into two strategic ventures that leverage its platform for nearer-term cash generation; first with Tonogold for the Lease-Option Agreement to lease and operate the facilities and second, with Mercury Clean Up LLC (“MCU”) for the commercial pilot of the MCU mercury remediation system.

Dayton Resource and Spring Valley Exploration Areas

During the third quarter of 2020, the Company engaged Geotech Ltd (“Geotech”) of Aurora, Canada, to conduct an airborne geophysical survey of the Dayton resource area, Spring Valley exploration targets, and the rest of the Company’s Comstock district properties. The survey included both magnetic and Geotech’s proprietary Versatile Time-Domain Electromagnetic (“VTEM”) surveys.

The survey was flown from September 19, through October 3, 2020, with 1,161 line-kilometers. The interpreted, three-dimensional results have been recently delivered to the Company and our geological team is just now assessing a deep trove of geophysical and geological data. The results will greatly increase the Company’s understanding of the Dayton resource area, the Spring Valley resource expansion potential, and the rest of the Company’s Comstock district properties.

The Company’s technical staff is currently compiling a detailed structural interpretation of the Dayton resource area, which will provide the framework for a completely new resource model. The detailed interpretation is leading to a list of highly prospective drill targets to further define and expand the mineral resource.

The Company is proceeding to publish a separate S-K 1300 compliant, Initial Assessment technical report for the Dayton resource area to validate a mineral resource estimate. The new technical report will provide not only a new resource estimate, but also a phased drilling plan for further defining and expanding the resource for sustainable, profitable mining. The Company plans to continually advance the Dayton to full feasibility, towards a production ready mine plan. Mining on lands 100% privately held by the Company should shorten the permitting cycle.

Corporate

During 2019, the Company received $6.1 million in Tonogold convertible preferred stock (“CPS”). The CPS became convertible into common shares on May 22, 2020. On May 22, 2020, and September 29, 2020, the Company elected to convert $1.1 million and $2.8 million of CPS, respectively, at $0.18 per common share, for a total of 21,777,778 common shares. Through November 13, 2020, the Company has sold 5,057,894 common shares at an average price of $0.40 per share for proceeds of over $2 million and still holds 16,719,884 shares.

On October 2, 2020, Tonogold redeemed the remaining $2.2 million of CPS for $2.6 million in cash, representing 120% of the CPS face value. The Company promptly reduced its debt from approximately $4.8 million at September 30, 2020, to approximately $2.5 million in early October.

The Company is also owed $4.5 million, in the form of a 12% note receivable, due and payable by Tonogold on September 20, 2021, plus Tonogold’s assumption of $6.7 million in future lease and reclamation obligations, that together represent a permanent reduction of annual operating expenses of approximately $1 million.

Cash and cash equivalents at September 30, 2020, were $1.7 million, total common shares outstanding at both September 30, 2020, and November 17, 2020, were 34,440,766 shares.

Outlook

The Company expects to monetize its non-mining assets over the next fifteen months, for over $22 million, net of debt. The Company expects to close on the sale of certain properties and senior water rights in Silver Springs, Nevada, to Sierra Springs Enterprises Inc., for total proceeds of approximately $10 million. The Company also expects to monetize the remaining $9.7 million in Tonogold securities over the next fifteen months and collect on the $4.5 million in notes receivable in the next 10 months. The Company will use the proceeds to extinguish the outstanding $2.5 million in debt obligations, plus accrued interest, and fund the Company’s growth initiatives.

The Company’s fourth quarter 2020 plans also include updating the Dayton’s current resource estimate and continuing southerly into Spring Valley with incremental exploration programs that include recently completed geophysical surveys, surface exploration and definition drilling of targets identified by the geophysical surveys, surface mapping, prior drilling and deeper geological interpretations that all lead to publishing a new, S-K 1300 compliant, mineral resource estimate.

The Company’s remaining 2020 plans include advancing the investment in and the commercialization of MCU’s mercury remediation processing technologies. The Company expects to close on the MCU transaction during the fourth quarter of 2020, meaning it will then own 15% of MCU and expects to close on the MCU Philippines transaction in the first quarter of 2021, meaning it will then own 25% of MCU and 50% of its first joint venture in the Philippines. Oro Industries Inc. has delivered the 25-ton-per-hour mercury recovery plant and is testing and preparing the system for its pilot operations on the Comstock, including a 200 gallon-per-minute dissolved air flotation water treatment plant. These pilot trial operations will continue throughout 2021, at the Company’s American Flat processing facility, to validate and fine-tune the mercury extraction and remediation process, with the objective of reclaiming and remediating the Company’s existing properties, enhancing the values of, and evaluating the potential economic feasibility for, these properties, and creating new global growth opportunities in mercury remediation by demonstrating MCU’s technological and operational effectiveness, efficiency, and feasibility.

MCU-P has delivered its first international system to the Philippines and plans to commence reclamation operations during the fourth quarter 2020. MCU-P will operate under a joint venture agreement with Clean Ore Solutions, a Philippine Company, for mercury extraction and remediation of Mount Diwalwal and the Naboc River, one of the most mercury polluted, gold mining regions in the world. This represents the first real international opportunity for large-scale mercury remediation and environmental reclamations, using MCU’s systems, and establishing MCU as a leader in mercury remediation projects, and in particular, contamination caused by artisanal and small-scale miners.

Conference Call

The Company will host a conference call today, November 17, 2020, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time. The live call will include a moderated Q&A, after the prepared comments by the Company. Please join the event 5-10 minutes prior to scheduled start time. When prompted, provide the confirmation code. The dial-in telephone numbers for the live audio are as follows:

Toll Free: 1-800-367-2403

Direct: 1-334-777-6978

Confirmation Code: 2739116
The audio will be available, usually within 24 hours of the call, on the Company’s new website:

http://www.comstockmining.com/investors/investor-library

About Comstock Mining Inc.

Comstock Mining Inc. is a Nevada-based, precious and strategic metal-based exploration, economic resource development, mineral production and metal processing business with a strategic focus on high-value, cash-generating, environmentally friendly, and economically enhancing mining and processing technologies and businesses. The Company has extensive, contiguous property in the historic Comstock and Silver City mining districts (collectively, the “Comstock District”) and is an emerging leader in sustainable, responsible mining and processing, and is currently commercializing environment-enhancing, metal-based technologies, products, and processes for precious and strategic metals recovery.

Forward-Looking Statements

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements, but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: consummation of all pending transactions; project, asset or Company valuations; future industry market conditions; future explorations, acquisitions, investments and asset sales; future performance of and closings under various agreements; future changes in our exploration activities; future estimated mineral resources; future prices and sales of, and demand for, our products; future impacts of land entitlements and uses; future permitting activities and needs therefor; future production capacity and operations; future operating and overhead costs; future capital expenditures and their impact on us; future impacts of operational and management changes (including changes in the board of directors); future changes in business strategies, planning and tactics and impacts of recent or future changes; future employment and contributions of personnel, including consultants; future land sales, investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives; the nature and timing of and accounting for restructuring charges and derivative liabilities and the impact thereof; contingencies; future environmental compliance and changes in the regulatory environment; future offerings of equity or debt securities; the possible redemption of debentures and associated costs; future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, earnings and growth.

These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: counterparty risks; capital markets’ valuation and pricing risks; adverse effects of climate changes or natural disasters; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration or mining activities; contests over title to properties; potential dilution to our stockholders from our stock issuances and recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting businesses; permitting constraints or delays; decisions regarding business opportunities that may be presented to, or pursued by, us or others; the impact of, or the non-performance by parties under agreements relating to, acquisitions, joint ventures, strategic alliances, business combinations, asset sales, leases, options and investments to which we may be party; changes in the United States or other monetary or fiscal policies or regulations; interruptions in production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, cyanide, water, diesel fuel and electricity); changes in generally accepted accounting principles; adverse effects of terrorism and geopolitical events; potential inability to implement business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors or others; assertion of claims, lawsuits and proceedings; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the SEC; potential inability to list our securities on any securities exchange or market; inability to maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund or any other issuer.

 

Contact information

Comstock Mining Inc.
1200 American Flat Rd
PO Box 1118
Virginia City, NV 89440
http://www.comstockmining.com

Corrado De Gasperis
Executive Chairman & CEO
Tel (775) 847-4755
degasperis@comstockmining.com

Zach Spencer
Director of External Relations
Tel (775) 847-5272 ext.151
questions@comstockmining.com

Edge Computing Importance to AI Applications

 

Mobile Artificial Intelligence is an Ever Expanding Technology

 

A child runs in front of you unexpectedly while you drive down your street. Your eyes see them and instantly send a signal to your brain. Your intelligent brain draws on a lifetime of related scenarios and almost instantly sends a signal down the neural pathways to your leg instructing it to hit the brake while perhaps simultaneously sending directions to your arms to alter your direction. All of these decisions were made onboard your vehicle with the most powerful computing tool you own, your brain.

Artificial Intelligence (AI)

Control is quickly being taken out of human hands (brains). Whether it be a driverless car, fighter jet, or any number of on-the-move AI applications.  Inventive ways of building onboard computing are working to fill this growing need. Artificial intelligence is nothing new, but it’s now being applied where the closer the “decision-maker” is to the situation, the faster the reaction time. In order to best suit all the new demands of AI, decision making power will very often need to be closer to the affected equipment. After all, your brain didn’t send a signal to the nearest 5G tower; that sent a signal to a server where the computing was done and then sent back to the 5G tower and to your leg to stop your car. All thinking and signaling was done within the space of a few feet. Onboard AI or edge computing strives to accomplish the same.

Edge Computing

Edge technology and its needed ruggedness has become necessary for domestic aircraft, military functions, and esports events to name a few applications. There is an expanding need. Edge is defined as small, lightweight, dense mainframe computing for a non-climate controlled, unfiltered, not bolted to the floor environment.  The market for edge is now estimated to be $18-$23 billion, and demand is growing.

One company that has carved out a place in edge computing is One Stop Systems (OSS). OSS designs and manufactures ultra-dense high-performance computing systems for learning, oil and gas exploration, trading, media and entertainment, defense, and traditional HPC applications. Equity Analyst Joe Gomes from Noble Capital Markets covers OSS. We spoke with Mr. Gomes yesterday to garner a bit more understanding about this technology, its potential, and specifically which areas of edge computing One Stop Systems specializes in.

 

Channelchek – How big is edge computing now, and what are the forecasts for its growth over the next few years?

 

Joe Gomes: Total Edge Computing market is about $18B, but OSS only currently plays in about $3 billion of this market. Existing space provides plenty of upside growth opportunities, and expansion into other parts of the edge computing market provides even larger growth opportunities. The market is growing by an estimated 26% from 2019-2027

 

Channelchek: Where is the biggest growth in edge computing, and specifically for OSS expected to come from?

 

Joe Gomes: Biggest growth will come from “AI on the fly” applications. AI on the fly provides actionable intelligence in real-time, on-site at the point of acquisition. We expect to see strong demand for such OSS products as flash array storage, GPU compute accelerators, and PCI express Gen 4 expansion product

 

Channelchek: Who are some of One Stop Systems’ larger customers or potential customers?

 

Joe Gomes: Some of the company’s larger clients historically have been Disguise, a media, and entertainment company that provides products for large in-person events (such as the Superbowl and concerts). Obviously, this is a difficult business currently with COVID. Raytheon, where OSS supplies flash storage arrays for military radar applications and has since worked its way onto additional military programs. Other key customers include Lyft and National Instruments

 

Channelchek: Working with Noble Capital Markets, Channelchek will be hosting a live presentation by OSS on November 19, discussing the company and fielding questions from the virtual audience. Is there anything specific that virtual attendees should listen for?

 

Joe Gomes: Well, the best advice I can give as a research analyst covering OSS is, if you have an interest in where this one aspect of the artificial intelligence world is trending that you should spend 40 minutes with us and maybe even ask questions this coming Thursday, Nov. 19 at 11 am EST.

 

Channelchek: Thank you, Joe.

 

Technologies that are changing the world often are developed where they grow and become providers to larger companies, who license that technology or acquired so larger, less creatively nimble companies benefit from synergies and patented technology. We encourage anyone with interest in mobile artificial intelligence and edge technology to join us. Details for virtual attendance are available below.

 

 

One Stop Systems (OSS)

Thursday November 19 11:00am EST

 

David Raun – CEO & John Morrison – CFO

Register Now

Release – Golden Predator (NTGSF, GPY:CA) – Completes 2020 Drill Program at Brewery Creek Mine Yukon

 

Golden Predator Completes 2020 Drill Program at Brewery Creek Mine, Yukon

 

Vancouver, BC, November 17, 2020: Golden Predator Mining Corp. (TSX.V:GPY, OTCQX:NTGSF) (the “Company”) today announces the completion of its 2020 work program at its licensed 100%-owned Brewery Creek mine project ?located approximately 55 km by road from Dawson City, Yukon. The 2020 program consisted of 60 drill holes for ~5,600 m of drilling including ~ 4,400 m of exploration and in-fill drilling plus 1,200 m of metallurgical and geotechnical drilling. All samples have been shipped and are currently being processed.

Brewery Creek maps can be viewed at: https://www.goldenpredator.com/_resources/news/GPY-NR-2020-Drill-Program-Completed-MAPS.pdf.

2020 Exploration and Technical Drill Program

The 2020 Brewery Creek drill program consisted of exploration, in-fill, geotechnical, hydrogeologic and metallurgical drilling to advance the Bankable Feasibility Study currently underway and projected for completion in Q1/21.

Infill Drilling

This program builds on Golden Predator’s successful 2019 program that established continuity of mineralization within the licensed Reserve Trend between the eastern edge of the Canadian-Fosters-Kokanee-Golden pits east to the Lucky pit. The 32 reverse circulation drill holes drilled in 2020 were designed to fill in and expand the gold resource between the eastern Golden zone and western Lucky zone. The targeted mineralization between these zones has been offset by a high-angle normal fault and was previously untested until 2019 when the zone was intersected with multiple drill holes.

Infill drilling within this 400 m gap between the eastern edge of the Fosters to Golden trend and the western edge of the Lucky zone is also to increase the density of drilling to convert Inferred resources to Indicated resources and confirm continuity of mineralization between the two deposits while testing for additional resources. The goal is to establish and confirm continuous mineralization along the Fosters-Canadian-Kokanee-Golden-Lucky zones for mine design now in progress as a part of the Brewery Creek Bankable Feasibility Study (BFS).

A total of 32 reverse circulation drill holes totaling 3,706 m were completed in the gap area between the eastern edge of Golden and western edge of Lucky. Samples from this program have been submitted to ALS Laboratories for sample preparation in Whitehorse, Yukon and assaying in Vancouver, British Columbia. Initial assay results from the program are expected in late November with complete assay results expected by the end of the year.

2020 Exploration Drilling of New Large-Scale Targets – Classic and Lonestar Zone

The 2020 drill program, targeted newly defined extensions of the Classic/Lone Star porphyry-style intrusive, with 3 reverse circulation holes totaling 687 m. The holes were very wide step-out holes drilled at significant distances from any existing drilling at the Classic and Lone Star areas.

Two of the drill holes (RC20-2710 and RC20-2711) were located approximately 500 m from each other and at least 650 m southeast of the closest previous drilling within the Classic and Lone Star zones. These holes targeted an area defined by anomalous gold and arsenic soil and rock chip geochemistry within a structural zone. The third drill hole (RC20-2711), located approximately 1,330 m to the east of the nearest previous drilling, tested a coincident aeromagnetic and radiometric anomaly indicating a structural zone along the margin of a biotite monzonite intrusive within an area of spotty gold and arsenic in soil geochemistry. All three drill holes encountered multiple fault zones and variable amounts of intrusive rock as dikes/sills within the structural zones.

The Classic Zone is a near surface bulk tonnage target that lies approximately 3 km south of the Brewery Creek Reserve Trend. Together with the Lone Star zone, the Classic Zone demonstrates the discovery potential of the entire southern portion of the large Brewery Creek Property where a large syenite intrusion hosts gold mineralization primarily in sheeted quartz/carbonate/pyrite veins and as fine-grained disseminations. Initial column leach tests have indicated that this intrusive hosted mineralization is leachable to at least a 200 m depth. This mineralization is clearly a separate younger mineralizing event not associated with the quartz monzonite thrust-hosted mineralization historically exploited in the Reserve Trend which is the subject of the ongoing bankable feasibility study.

Metallurgical & Geotechnical Drilling

A total of 14 PQ diamond drill holes totaling 540 m were completed in Foster-Canadian-Kokanee-Golden and Lucky pit areas. The program was designed to obtain mineralized material from the Fosters, Kokanee, Golden and Lucky areas for additional column leach tests. The core was shipped to McClelland Labs in Reno, NV where it is currently being tested. The core samples will be used to conduct additional column leach tests at a coarser crush size of approximately 3/4” versus previous test work conducted at 3/8” crush size at Kokanee, Golden and Lucky. These column tests are being conducted to confirm the recent results of column leach tests run at various crush sizes on material from the historic heap leach pad where the data showed slightly better recoveries of gold in solution for the coarser 3/4” crush size. A coarser crush size would help streamline any recovery process. These tests will be detailed in the Bankable Feasibility Study currently underway.

A total of eleven geotechnical/hydrogeologic drill holes were completed to support the ongoing Bankable Feasibility Study at Brewery Creek. A total of 975 m of drilling was completed in 8 diamond drill holes (792 m) and 3 reverse circulation drill holes (182 m). The diamond drill program was consisted of oriented, HQ3 core to support detailed fracture analysis of lithologies in the proposed pit walls and three of these were completed with piezometers. The 3 reverse circulation drill holes were drilled and completed as hydrogeologic monitor wells.

Brewery Creek Mine: Resources

Materials on the heap leach pad were not included in the resource update.
Mineral Resources estimates conducted within a pit shell developed at $2,000/oz gold with an internal cut-off grade calculated at $1,500/oz gold was used to report mineral resource inventories

The resource estimate is based on a recovery model created from assay data, bottle and column leach test work and historic recovery analysis instead of a less accurate visual oxide-sulfide boundary developed from geologist drill logs. Sedimentary and intrusive rocks, which have distinct metallurgical characteristics, were estimated separately based on gold-grade distribution analysis.

The current 2020 Mineral Resources Estimate supersedes the 2019 Mineral Resource Estimate. A supporting NI 43-101 Technical Report is filed on SEDAR at www.sedar.com.

Brewery Creek Mine Work Plan

The Brewery Creek Mine is a licensed brownfields heap leach gold mine that was operated by Viceroy Minerals Corporation from 1996 to 2002. Brewery Creek is authorized to restart mining activities as defined within the Quartz Mining License and Water License. The Company intends to resume mining and processing of licensed deposits when supported by an independent study that outlines technical and economic viability. The 180 km2 property is located 55 km east of Dawson City and is accessible year-round by paved and improved gravel roads. Significant infrastructure remains in place, allowing for a timely restart schedule under existing operating licenses.

A Bankable Feasibility Study (BFS) is being conducted by Kappes Cassiday & Associates of Reno, Nevada which will include a multi-year mine plan for the advancement of the Brewery Creek project. The BFS will include an inventory of the mineralized material remaining on the heap and mine planning (completed by Tetra Tech Inc of Golden, Colorado) for the resumption of the mining of material from leachable resources contained within the licensed area and reported in the Company’s Mineral Resource Estimate. The BFS will include all the key parameters involved in reconstructing or adding necessary infrastructure including a crushing facility, the Adsorption-Desorption-Recovery (“ADR”) plant and assay lab and an implementation schedule, sourcing, and economic cash flow model sufficiently detailed to move directly into procurement, development and construction if economically warranted. Any production decisions would be dependent on the outcome of a study demonstrating positive technical and economic viability.

The technical content of this news release has been reviewed and approved by Michael Maslowski, CPG, a Qualified Person as defined by National Instrument 43-101 and is employed by the Company as its Chief Operating Officer.

About Golden Predator Mining Corp.

Golden Predator is advancing the past-producing Brewery Creek Mine towards a timely resumption of mining activities, under its Quartz Mining and Water Licenses, in Canada’s Yukon. With established resources grading over 1.0 g/t gold the Company is completing a Bankable Feasibility Study for the restart of heap leach operations. The Brewery Creek Mine project operates with a Socio Economic Accord with the Tr’ondëk Hwëch’in First Nation.

 

For additional information:
Janet Lee-Sheriff
Chief Executive Officer
(604) 260-8435
info@goldenpredator.com

www.goldenpredator.com

 

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This press release contains forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations that the Brewery Creek will advance to an early production decision, or the extent of any additional mineral resource that could result from incorporating 2019 exploration drilling. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward looking information should circumstances or management’s estimates or opinions change.

1. 1. The 2020 Mineral Resource Estimate was conducted in accordance with CIM guidelines and is reported in a NI 43-101 Technical Report which will be filed on SEDAR and the Company’s website within 45 days.

Source: Golden Predator Mining Corp.

EuroDry Ltd. (EDRY) – A Solid Quarter – Looking Ahead to 2021

Tuesday, November 17, 2020

EuroDry Ltd. (EDRY)

A Solid Quarter – Looking Ahead to 2021

EuroDry Ltd. was formed on January 8, 2018 under the laws of the Republic of the Marshall Islands and trades on the NASDAQ Capital Market under the ticker EDRY. EDRY is the product of a spin-off of the dry bulk fleet by Euroseas (ESEA) completed in May 2018. For every five ESEA shares, ESEA shareholders received one EDRY share. There are currently ~2.2 million EDRY shares outstanding. EuroDry operates in the dry bulk shipping markets. EuroDry’s operations are managed by Eurobulk Ltd., an affiliated ship management company, and Eurobulk FE (Far East) Ltd, which are responsible for the day-to-day commercial and technical management and operation of the fleet. EuroDry employs the fleet on spot and period charters and through pool arrangements.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Adjusted 3Q2020 EBITDA stronger than expected due to higher TCE rates. 3Q2020 EBITDA of $2.8 million improved from 2Q2020 EBITDA of $0.2 million in 2Q2002 as TCE rates jumped to $11,873/day from $7,297/day in 2Q2020. Versus expectations, TCE revenue of $7.6 million was well above expectations by $1.9 million, as TCE rates tied to indices were higher than expected. The fleet of 7.0 vessels did not change and ownership days were 644, while TCE rates jumped to $11,873/day from $7,297/day in 2Q2020.

    Fine-tuning 2020 estimate to incorporate 3Q2020 operating results and current dry bulk market conditions.  We are moving our adjusted 2020 EBITDA estimate to $5.7 million based on TCE rates of $9,100/day, up from $5.4 million based on TCE rates of $8,724/day. While TCE rates were higher than expected in 3Q2020, we are forecasting that TCE rates fall back slightly in 4Q2020 …



This research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Cocrystal Pharma (COCP) – Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

Cocrystal Pharma Reports Third Quarter 2020 Financial Results and Provides Update on Antiviral Programs

 

– Continued progress of COVID-19 development programs with additional preclinical studies of coronavirus protease inhibitors (3CL) underway and lead preclinical molecule selection expected by year end –

– Ongoing Merck collaboration to discover and develop influenza A/B antiviral agents –

– Continued advancement of wholly owned Influenza A development program and IND enabling studies towards Phase 1 clinical study in 2021–

– Successful completion of strategic financing fuels expansion of COVID-19 and Influenza A development programs –

 

BOTHELL, WA, Nov. 16, 2020 (GLOBE NEWSWIRE)Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced its financial results for the quarter ended September 30, 2020 and provided program updates.

Recent Highlights

  • Announced promising in vitro and 7-day toxicity data for its influenza A preclinical lead molecule, CC-42344.
  • Announced new in vitro data demonstrating antiviral activity with lead compound CC-42344 against major Xofluza (baloxavir)-resistant H1N1 strain (I38T).
  • Presented at the virtual World Antiviral Conference held on November 12, 2020.
  • Closed $17.2 million bought deal including partial exercise of underwriter’s overallotment option.
  • Publication by collaborators of data demonstrating potent in vitro inhibition against Coronavirus in Science Translational Medicine Journal (August 3, 2020).

“We have made significant progress since initiating our COVID-19 program this year by strengthening our patent portfolio around these molecules, conducting a proof of concept animal study, initiating preclinical studies and identifying additional inhibitors using our proprietary platform. Over the course of the last quarter we continued to make progress on multiple fronts. We are pleased with the promising new data we recently announced for our wholly owned influenza A development program and continue to work towards finalizing the Phase 1 study protocol in preparation to initiate the Phase 1 study in 2021,” commented Dr. Gary Wilcox, Chairman and Chief Executive Officer of Cocrystal. “In addition to advancing our development programs, we closed the quarter with $31.8 million cash, which provides funding for the expansion of our COVID-19 and influenza A programs. Our team remains keenly focused on executing our milestones to drive shareholder value.”

Development Programs Overview

COVID-19 Coronavirus Programs:
We have two programs that are aggressively pursuing the development of novel antiviral compounds for the treatment of coronavirus infections.

Our first program is with compounds licensed from Kansas State University Research Foundation (“KSURF”) that have demonstrated in vitro anti-SARS-CoV-2 (responsible for the COVID-19 pandemic) activity, and in vivo efficacy in MERS-CoV-infected animal models. Cocrystal continued preclinical studies of these COVID-19 inhibitors during the third quarter. We anticipate the selection of a lead preclinical molecule by the end of 2020.

Our second program in Covid-19 has identified additional inhibitors using Cocrystal’s proprietary platform technology.

We are evaluating multiple routes of administration of COVID-19 antivirals.

Influenza A/B Inhibitors: Merck Collaboration
We have an exclusive license and collaboration agreement with Merck to discover and develop proprietary influenza A/B antiviral agents.

Cocrystal’s exclusive license and collaboration agreement with Merck Sharp & Dohme Corp. (“Merck”) to discover and develop proprietary influenza A/B antiviral agents is ongoing. Merck has funded the collaborative influenza A/B program and could potentially provide up to $156 million in milestone payments through clinical and commercial development, plus royalties following commercialization.

The collaboration operates under a Research Operating Plan which includes goals for both organizations. The Company has achieved its anticipated goals through the third quarter of 2020.

CC-42344: Influenza A Program:
Novel, broad spectrum influenza antivirals that are specifically designed to be effective against pandemic and seasonal influenza A strains of the influenza virus and to have a high barrier to resistance due to its novel mechanism of action.

The Company’s fully owned drug candidate CC-42344 is a potent, broad spectrum inhibitor of the influenza replication enzyme targeting the PB2 subunit, and has strong synergistic effects when combined with approved influenza antiviral drugs including Tamiflu (oseltamivir) and Xofluza (baloxavir). Cocrystal has data showing that CC-42344 retained single digit nanomolar potency (EC50 = 0.5 nM) against a Xofluza (baloxavir) resistant influenza A strain (H1N1, I38T). This data can potentially show CC-42344 drug superiority when seeking FDA approval.

The Company plans to complete the ongoing IND-enabling studies and enter into clinical trials in 2021.

CC-31244: Hepatitis C Program:
Potential best-in-class pan-genotypic inhibitor of NS5B polymerase for the ultra-short combination treatment of hepatitis C infection.

The Company is pursuing partnering opportunities for CC-31244. The final study report of Cocrystal’s U.S. Phase 2a clinical trial evaluating CC-31244 combination therapy for the ultrashort treatment of hepatitis C virus (“HCV”) infected individuals has been completed and filed with the FDA. The Company has published with its collaborators from the University of Maryland the results of the Phase 2a study (Journal of Medical Virology, November 5, 2020).

Norovirus Program:
Developing inhibitors targeting Norovirus RNA-dependent RNA polymerase and protease.

Cocrystal continues to identify and develop non-nucleoside polymerase and protease inhibitors using its proprietary structure-based drug design technology platform. Cocrystal recently entered into license agreements with KSURF to further develop proprietary broad-spectrum protease inhibitors to treat Norovirus and Coronavirus infections.

Summary of Financial Results for Q3 2020

As of September 30, 2020, Cocrystal had approximately $31,781,000 cash on hand.

Revenue recorded for the three and nine months ended September 30, 2020 was $489,000 and $1,504,000, respectively, compared with $492,000 and $6,162,000 for the three and nine months ended September 30, 2019, respectively. The revenue difference for the nine months ended September 30, 2019 is because that period included $4,368,000 in initial revenue of intellectual property rights conveyed at the signing of the Merck Collaboration Agreement executed on January 2, 2019.

Research and development expenses for the three and nine months ended September 30, 2020 were $2,077,000 and $5,336,000, respectively, compared with $1,077,000 and $3,046,000 for the three and nine months ended September 30, 2019, respectively. The increase for the three and nine months ended September 30, 2020 compared to the three and nine months ended September 30, 2019 was primarily due to initiating our COVID-19 program and advancing our Influenza A program in preparation for clinical trials in 2021.

General and administrative expenses for the three and nine months ended September 30, 2020 were $1,121,000 and $4,288,000, respectively, compared with $1,223,000 and $3,597,000 for the three and nine months ended September 30, 2019, respectively. The decrease for the three months ended September 30, 2020 compared to the three months ended September 30, 2019 was primarily due to decreased litigation costs during the 2020 three-month period. The increase for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019 was primarily due to higher litigation costs, insurance increases and employee compensation in the first half of 2020.

Net loss for the three and nine months ended September 30, 2020 was $2,670,000 and $8,155,000, respectively, compared with a net loss of $1,780,000 and $324,000 for the three and nine months ended September 30, 2019, respectively, as a result of revenue and expenses described above.

About Cocrystal Pharma, Inc.

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, SARS-CoV-2 virus, hepatitis C viruses, and norovirus. Cocrystal employs unique, proprietary, structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the expected progress of, and the anticipated timing of achieving the value-driving milestones in, our coronavirus program, including the selection of a preclinical lead molecule in Q4 2020; the expected progress of, and the anticipated timing of achieving the value-driving milestones in, our Influenza A program, including the completion of the ongoing IND-enabling studies and commencement of Phase 1 clinical study in 2021; our expectations with respect to CC-42344 drug superiority; and the expected results of our collaboration with Merck, including the potential future milestone payments of up to $156,000,000 and royalties in connection with the collaboration. The words “believe,” “proceeds,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks arising from the impact of the COVID-19 pandemic on the national and global economy and on our Company, including supply chain disruptions, our continued ability to proceed with our programs, our reliance on certain third parties, our reliance on continuing with Merck under the license and collaboration agreement, the future results of preclinical and clinical studies, general risks arising from clinical trials, receipt of regulatory approvals, and development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2019, as updated and supplemented by the Quarterly Reports on Form 10-Q for the quarters ended September 30, 2020 and June 30, 2020. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Additional factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Investor and Media Contact:

JTC Team, LLC
(833) 475-8247
COCP@jtcir.com

Source: Cocrystal Pharma, Inc.

Golden Predator Mining (NTGSF)(GPY:CA) – 2020 Drilling Program Completed Assay Results Pending

Monday, November 16, 2020

Golden Predator Mining (NTGSF)(GPY:CA)

2020 Drilling Program Completed; Assay Results Pending

Golden Predator Mining Corp is a Canada based exploration stage company engaged in the business of acquiring and exploring mineral properties. It owns properties primarily in Yukon, Canada. Some of the company’s projects located in Yukon are the 3 Aces, Sprogge, Reef, Brewery Creek, Marg, Sonora Gulch, Grew Creek, Upper Hyland and others.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Assay results pending. Golden Predator completed its 2020 drilling program, which commenced in September, and included a reverse circulation drilling program, along with a metallurgical core drilling program. In aggregate, 60 holes were drilled representing 5,900 meters of drilling. Final assay results are expected in December. Drilling focused on connecting the Keg pit that combines the Canadian, Fosters, Golden and Kokanee deposits into one elongated pit with a fifth deposit known as Lucky. Core drilling samples will be used in leach column tests to confirm whether a coarser crush size results in better recoveries of gold.

    Bankable feasibility study (BFS) expected in Q1-21.  A BFS is being completed by Kappes Cassiday & Associates and will include a multi-year mine plan for the advancement of the Brewery Creek project. The BFS will include an inventory of material on the heap to be re-processed and a plan to resume mining of material from leachable resources contained within the licensed area …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Newrange Gold (NRGOF)(NRG:CA) – Drilling Pauses to Allow for Receipt and Analysis of Assay Results

Monday, November 16, 2020

Newrange Gold (NRGOF)(NRG:CA)

Drilling Pauses to Allow for Receipt and Analysis of Assay Results

As of April 24, 2020, Noble Capital Markets research on Newrange Gold is published under ticker symbols (NRGOF and NRG:CA). The price target is in USD and based on ticker symbol NRGOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target.

Newrange Gold Corp is an exploration stage company focused on acquiring and exploring exploration and evaluation assets in Colombia and the United States. The Company operates in a single reportable operating segment-the acquisition, exploration, and development of mineral properties. Some of the projects acquired by the company are Pamlico gold project in Nevada and Rocky mountain project in Colorado. The company also holds an interest in the Yarumalito property, El Dovio property and Anori property in Colombia.

Mark Reichman, Senior Research Analyst of Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    Significant progress to date. Since beginning the drilling program in late May, Newrange has drilled 65 holes for a total of 6,538 meters. Assay results for the last 26 holes are pending. Following a first phase of drilling that included 3,462 meters of drilling along Pamlico Ridge, drilling resumed on September 19 and the company drilled seven holes at Gold Box Canyon, seven holes in the Merritt area, eight drill holes at the Good Hope Mine, six holes at the Gold Bar and Pamlico Mines, and two drill holes on anomalies identified in an induced polarization (IP) survey. The company decided to take a break from drilling until the remaining assays results can be interpreted and a follow-up drilling program planned.

    More drilling planned.  Newrange expects to drill at least another 3,000 meters in approximately 20 holes that range in depth from 75 to 465 meters to follow up on recent drilling with multiple holes planned to test a large chargeability anomaly near the center of the property. Drilling is expected to resume on or about December 5 …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

InPlay Oil (IPOOF)(IPO:CA) – The road to normal

Monday, November 16, 2020

InPlay Oil (IPOOF)(IPO:CA)

The road to normal

As of April 24, 2020, Noble Capital Markets research on InPlay Oil is published under ticker symbols (IPOOF and IPO:CA). The price target is in USD and based on ticker symbol IPOOF. Research reports dated prior to April 24, 2020 may not follow these guidelines and could account for a variance in the price target. InPlay Oil is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQZ Exchange under the symbol IPOOF.

Michael Heim, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

    IPO reported operating and financial results in line with expectations. Production of 3,742 boe/d vs. our 3,871 est. Oil prices were slightly below model ($39.51 vs $43.00) but gas prices were above ($2.32 vs $1.52). Sales of $10.8 mm vs. $10.9 mm. LOE of $14.42 vs. $14.18. Earnings of ($2.7 mm)/($0.04) vs. ($3.2 mm)/($0.05). All in all, a very straightforward quarter.

    Other developments were preannounced November 2.  InPlay’s $25 million bank loan is moving forward, a small $1.9 mm tuck-in acquisition closed, 4Q budget includes drilling 3 wells that will move production levels to pre-Covid rates of 5,000 boe/d. Only new development was that a ban on road construction will push drilling and the 5,000 target into the first quarter instead of year end …



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision. 

Release – Lineage Cell Therapeutics (LCTX) – Presents New OpRegen Data for Dry AMD With GA at 2020 American Academy of Ophthalmology Annual Meeting

 

Lineage Cell Therapeutics Presents New Opregen® Data For Dry Amd With Ga At 2020 American Academy Of Ophthalmology Annual Meeting

 

  • Improved Visual Acuity Continues to be Observed in Cohort 4 Patients
  • First Known Clinical Report of Retinal Tissue Regeneration Persisted to 23 Months with Further Improvement in Visual Acuity
  • Patient Enrollment Recently Completed
  • Therapeutic Expert Call with Principal Investigator Christopher D. Riemann, M.D. Scheduled for November 17, 2020 at 4:00 pm Eastern Time

CARLSBAD, Calif.–(BUSINESS WIRE)–Nov. 16, 2020– Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing three novel cell therapies for serious medical conditions, today announced positive interim results from the ongoing 24-patient Phase 1/2a clinical study of Lineage’s lead product candidate, OpRegen®. OpRegen is an investigational cell therapy consisting of allogeneic retinal pigment epithelium (RPE) cells administered to the subretinal space for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA). At AAO, new data were presented on 20 patients, including 8 patients treated in Cohort 4, which feature better baseline vision and smaller areas of GA. All 8 of these patients were treated with a new “thaw-and-inject” formulation of OpRegen and 4 were treated using the Gyroscope Orbit Subretinal Delivery System (Gyroscope SDS). Data presented at AAO showed improvements in visual acuity in Cohort 4 patients, with treated versus fellow eye comparisons reaching statistical significance at 9 and 12 months following OpRegen administration. These improvements were maintained for up to 24 months in some patients. A trend towards slower GA growth was observed in the first 6 Cohort 4 patients, a trend maintained for as long as 24 months in patients with 24-month data available. Previously reported structural improvements in the retina and decreases in drusen density have continued with evidence of durable engraftment of OpRegen cells in treated patients, some more than 4 years following administration, with no immunosuppression utilized beyond the perioperative period. Overall, OpRegen appears to be well-tolerated in all patients treated to date. The final four patients in the study were treated during November and will provide additional visual acuity data in the coming months.

“These new data increasingly suggest to us that treatment with OpRegen can provide clinically meaningful outcomes in dry AMD patients with GA, particularly for those with earlier-stage disease,” stated Brian M. Culley, Lineage CEO. “According to a recent survey published in Investigative Ophthalmology & Visual Science, only 27% percent of retinal specialists believed patients with visual acuity of 20/200 or worse could benefit from treatment with an agent which slows the growth of GA, while 93-99% of them believed patients with visual acuity of 20/200 or better could benefit from this approach. This is consistent with our belief that recent data from our Cohort 4 patients, which have less advanced disease and better baseline vision, are more exciting and provide a better surrogate for the potential clinical and commercial opportunity for OpRegen.”

Mr. Culley added, “In addition to reporting the first known finding of anatomical restoration of retinal tissue, which has persisted below baseline for 23 months and counting, treatment with OpRegen continues to demonstrate other benefits in some patients, including increases in visual acuity, reductions in the growth rate of GA and increases in reading speed. These are additive to the improvements we previously reported in retinal architecture and drusen reduction. Further, the multi-year durability of transplants without rejection is notable for our allogeneic cell therapy approach, especially as patients did not require long-term immunosuppression. With enrollment recently completed, our focus turns next toward collecting safety and efficacy data on the most recently treated patients, advancing partnership and investor discussions we’ve been having, exploring our options for later-stage clinical development, and speaking with the FDA about next steps. Our objective is to position the OpRegen program as a front-runner in the race to address an unmet need in what is widely expected to be a multi-billion-dollar dry AMD therapeutic market and to drive Lineage forward as the pre-eminent allogeneic cell therapy company.”

OpRegen Data Update & Highlights from the AAO Presentation (data presented on 20 patients, dosed through October 5, 2020):

  • Continued progressive functional improvement.
    • In Cohort 4, 6 out of 7 (86%) of patients’ treated eyes measured above their baseline vision (Best Corrected Visual Acuity, or BCVA) at 12 months, a clinically relevant timeframe, or as of the longest available timepoint less than 12 months (data collection continues for more recently-treated patients).
    • Data to date demonstrate a localized slowing of GA progression in the treated areas with a trend towards slower GA growth in treated versus fellow eyes in pooled analyses.
  • Long-term engraftment is supported with imaging observations up to more than 4 years, even with a short immunosuppression regimen.
    • In all Cohort 4 patients receiving OpRegen TAI formulation, per protocol, immunosuppressants have been discontinued as scheduled, typically within 90 days post-operatively, and no cases of acute or delayed rejection or inflammation have been reported.
    • One Cohort 4 patient was treated only with mycophenolate mofetil and received no tacrolimus for immunosuppression.
  • Anatomical restoration of retinal tissue.
    • A Cohort 4 patient with evidence of retinal restoration and confirmed history of GA growth, which was first reported at 9 months, continues at month 23 to have an area of GA smaller than at baseline.
    • This patient also experienced additional improvement in BCVA from 9 to 23 months post-treatment, while the untreated eye has experienced further reduction in visual acuity.
    • Long-term monitoring on this patient is expected to continue.
  • Treatment overview.
    • As of October 5, 2020, 16 patients were treated via pars planar vitrectomy (PPV), while 4 were treated with the Gyroscope SDS.
    • As of November 10, 2020, 17 patients were treated via PPV, while 7 were treated with the Gyroscope SDS.
    • Enrollment in the phase 1/2a study is complete; follow-up continues for safety and efficacy.
  • Safety and tolerability.
    • The primary objective of the study is to evaluate the safety and tolerability of OpRegen at 12 months, and in patients which have reached this time point OpRegen appears well tolerated.
    • There have been no unexpected adverse events (AEs) or treatment-related systemic serious AEs reported in enrolled patients.
    • The most common and expected ocular AEs were the formation or exacerbation of mild to moderate epiretinal membranes (ERMs) and a single report of a retinal detachment, with cause unknown (all occurring in patients receiving OpRegen via the PPV route of administration).
    • The Gyroscope SDS is an alternative to the PPV route and is designed to avoid ERM formation.
      • Through October 2020, 16 patients were treated via PPV while 4 were treated with the Gyroscope SDS. ERMs were observed in 13 PPV patients.
      • One patient treated with the Gyroscope SDS developed a mild choroidal neovascularization (CNV) at the site of needle penetration 6 months post-treatment which was successfully treated with a single dose of an approved anti-VEGF agent. The cause was unknown.
      • One patient treated via PPV developed a mild CNV at > 24 months post-treatment.
    • Other changes observed following OpRegen treatment persisted through the last time point examined (> 4 years in some patients), including subretinal pigmentation and hyper-reflective areas seen on optical coherence tomography (OCT).

The results were presented at the 2020 American Academy of Ophthalmology Annual Meeting (AAO 2020). The presentation, “Phase 1/2a Study of Subretinally Transplanted hESC-Derived RPE Cells in Advanced Dry-Form AMD Patients” was featured as part of the Original Paper Session, OP02V Retina, Vitreous Original Papers on November 15, 2020 and was presented by Christopher Riemann, M.D.

KOL Call and Webcast

Lineage will host a therapeutic area expert call with Christopher D. Riemann, M.D., Vitreoretinal Surgeon and Fellowship Director, Cincinnati Eye Institute and University of Cincinnati School of Medicine, to discuss the interim results on November 17, 2020 at 4:00 pm Eastern Time / 1:00 p.m. Pacific Time. Interested parties can access the event on the Events and Presentations section of Lineage’s website.

About OpRegen

OpRegen is currently being evaluated in a Phase 1/2a open-label, dose escalation safety and efficacy study of a single injection of human retinal pigment epithelium cells derived from an established pluripotent cell line and transplanted subretinally in patients with advanced dry AMD with GA. The study enrolled 24 patients into 4 cohorts. The first 3 cohorts enrolled only legally blind patients with best corrected visual acuity (BCVA) of 20/200 or worse. The fourth cohort enrolled 12 better vision patients (vision from 20/65 to 20/250 with smaller areas of GA). Cohort 4 also included patients treated with a new “thaw-and-inject” formulation of OpRegen, which can be shipped directly to sites and used immediately upon thawing, removing the complications and logistics of having to use a dose preparation facility. In total, 17 patients were treated via PPV, while 7 were treated with the Gyroscope SDS. The primary objective of the study is to evaluate the safety and tolerability of OpRegen as assessed by the incidence and frequency of treatment emergent adverse events. Secondary objectives are to evaluate the preliminary efficacy of OpRegen treatment by assessing the changes in ophthalmological parameters measured by various methods of primary clinical relevance. Additionally, for the patients in Cohort 4 that receive subretinal delivery of OpRegen utilizing the Gyroscope SDS, objectives will include the evaluation of the safety of delivery of OpRegen using the Gyroscope SDS.

OpRegen is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of Lineage Cell Therapeutics, Inc.

About Dry AMD

Dry age-related macular degeneration (AMD) is a leading cause of adult blindness in the developed world. There are two forms of AMD: wet AMD and dry AMD. Dry AMD is the more common of the two types, accounting for approximately 85-90% of cases. Wet AMD is the less common of the two types, accounting for approximately 10-15% of cases. Global sales of the two leading wet AMD therapies were in excess of $10 billion in 2019. Nearly all cases of wet AMD begin as dry AMD. Dry AMD typically affects both eyes. There are currently no U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA) approved treatment options available for patients with dry AMD.

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.

Forward-Looking Statements

Lineage cautions you that all statements, other than statements of historical facts, contained in this press release, are forward-looking statements. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the negative version of these words and similar expressions. Such statements include, but are not limited to, statements relating to Lineage’s expected eligibility for grants. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Lineage’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including risks and uncertainties inherent in Lineage’s business and other risks in Lineage’s filings with the Securities and Exchange Commission (the SEC). Lineage’s forward-looking statements are based upon its current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. Further information regarding these and other risks is included under the heading “Risk Factors” in Lineage’s periodic reports with the SEC, including Lineage’s Annual Report on Form 10-K filed with the SEC on March 12, 2020 and its other reports, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Lineage undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Lineage Cell Therapeutics, Inc. IR
Ioana C. Hone
(ir@lineagecell.com)
(442) 287-8963

Solebury Trout IR
Gitanjali Jain Ogawa
(Gogawa@troutgroup.com)
(646) 378-2949

Russo Partners – Media Relations
Nic Johnson or David Schull
Nic.johnson@russopartnersllc.com
David.schull@russopartnersllc.com
(212) 845-4242

Source: Lineage Cell Therapeutics, Inc.

Type-1 Diabetes – The Beginning of the End Close to a Cure

In 1988 Dr. Camillo Ricordi (above) revolutionized a method of transplantation of islet cells (cells that produce insulin) which remains the gold standard for human pancreas processing today. The problem is, like with so many other types of transplantation, the body often rejects the new cells. All that could change with the introduction of this anti-rejection antibody – Novus Therapeutics, Inc. (NASDAQ:NVUS) – CD40/CD40L – FDA Phase II.

Join Dr. Ricordi and his world-class panel of experts who will weigh-in on the likelihood of this medical breakthrough. They’ll also look at what the future may hold for investors in the technology, and those who are considering an investment. It’s T1D-Day, with the hopeful surrender of this debilitating disease just around the corner.

November 24, 2020

Watch The Replay

Premium Content Available to Registered Users – Registration is Free

 

Panelists (left to right): Dr. Camillo Ricordi, Director of the Diabetes Research Institute at the University of Miami School of Medicine – Ranked as the World Leader in Islet Cell Transplant; Dr. James Markmann, Chief of the Division of Transplant Surgery and Director of Clinical Operations at the Transplant Center at Massachusetts General Hospital, and the Claude Welch Professor of Surgery at Harvard Medical School; Dr. Norma Sue Kenyon, Martin Kleiman Professor of Surgery, Microbiology and Immunology and Biomedical Engineering, Vice Provost for Innovation; Dr. David Gros, Chief Executive Officer Novus Therapeutics; Dr. Steven Perrin, President & CSO, Novus Therapeutics, and; Eric Paslay, award-winning country recording artist (T1 diabetic who will provide a patient perspective).

 

Moderator: Nathan Cali, Head of Healthcare Investment Banking, Noble Life Science Partners (a division of Noble Capital Markets).

 

November is National Diabetes Month, a time when communities across the country team up to bring attention to diabetes. This year’s focus is on taking care of youth who have diabetes.

 



Scientific support from:

©2020 Noble Capital Markets

Disclosures: Noble Capital Markets, Inc. (“Noble”) is a FINRA / SEC registered broker-dealer and the provider of equity research on Channelchek. On September 14, 2020, Novus Therapeutics, Inc.(“Novus”) acquired Anelixis Therapeutics, Inc. (“Anelixis”). Prior to the acquisition, and in the last twelve months, Anelixis retained Noble as a placement agent and financial advisor, and as such, Noble was compensated. In the next twelve months, Noble may be retained by Novus and receive compensation for services it may render. Nathan Cali, Head of Healthcare Investment Banking at Noble (moderator of the panel), was previously an Anelixis Observer Board Member. Dr. Camillo Ricordi (“Ricordi”) has been compensated by Noble as a Scientific Advisor in the past twelve months. Ricordi and Dr. James Markmann serve or have served as scientific advisors or consultants to Novus in the past twelve months. Ricordi has been compensated by Novus for his role. The T1D-Day panel is presented as informational only and does not constitute an offer or solicitation to buy or sell securities. There is no suggestion or obligation for attendees to act on any of the information discussed by the panel.

 


Members FINRA | SIPC | MSRB